Aerocrine Provides Update On Insurance Coverage Of Feno Test In US.

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SOLNA, Sweden - 19 March, 2014 - Aerocrine AB (OMX Nordic Exchange: AERO) announces that Health Care Service Corporation will begin covering FeNO testing for asthma diagnosis and management effective April 1, 2014. Aerocrine has received notification that Health Care Service Corporation (HCSC) will implement a positive coverage policy for Fractional exhaled Nitric Oxide (FeNO) testing for the diagnosis and management of asthma effective April 1, 2014. HCSC, the 5th largest private payer in the US, provides insurance coverage for 14 million individuals. HCSC subsidiaries include Blue Cross and Blue Shield plans of Illinois, Montana, New Mexico, Oklahoma, and Texas.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC